Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
The closing price of Cytek BioSciences Inc (NASDAQ: CTKB) was $4.02 for the day, up 1.01% from the previous closing price of $3.98. In other words, the price has increased by $1.01 from its previous closing price. On the day, 0.71 million shares were traded. CTKB stock price reached its highest trading level at $4.1 during the session, while it also had its lowest trading level at $3.91.
Ratios:
Our analysis of CTKB’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.95 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 47.05. For the most recent quarter (mrq), Quick Ratio is recorded 4.55 and its Current Ratio is at 5.22. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.06.
On January 31, 2025, Goldman Downgraded its rating to Sell which previously was Buy and also lowered its target price recommendation from $7 to $4.50. On December 14, 2023, Stephens started tracking the stock assigning a Overweight rating and target price of $9.Stephens initiated its Overweight rating on December 14, 2023, with a $9 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 02 ’25 when McCombe William D. bought 35,000 shares for $2.78 per share. The transaction valued at 97,300 led to the insider holds 55,746 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTKB now has a Market Capitalization of 511440480 and an Enterprise Value of 273097600. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.61 while its Price-to-Book (P/B) ratio in mrq is 1.35. Its current Enterprise Value per Revenue stands at 1.393 whereas that against EBITDA is -12.419.
Stock Price History:
The Beta on a monthly basis for CTKB is 1.36, which has changed by -0.2623853 over the last 52 weeks, in comparison to a change of 0.18469036 over the same period for the S&P500. Over the past 52 weeks, CTKB has reached a high of $7.63, while it has fallen to a 52-week low of $2.37. The 50-Day Moving Average of the stock is 7.69%, while the 200-Day Moving Average is calculated to be -10.05%.
Shares Statistics:
CTKB traded an average of 1.18M shares per day over the past three months and 1037380 shares per day over the past ten days. A total of 127.19M shares are outstanding, with a floating share count of 115.53M. Insiders hold about 9.20% of the company’s shares, while institutions hold 62.65% stake in the company. Shares short for CTKB as of 1755216000 were 5668706 with a Short Ratio of 4.79, compared to 1752537600 on 5648731. Therefore, it implies a Short% of Shares Outstanding of 5668706 and a Short% of Float of 5.79.
Earnings Estimates
Current recommendations for the stock of the company come from 2.0 analysts. The consensus estimate for the next quarter is $0.04, with high estimates of $0.04 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.04 and $0.03 for the fiscal current year, implying an average EPS of $0.04. EPS for the following year is $0.03, with 2.0 analysts recommending between $0.05 and $0.01.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $52.7M to a low estimate of $51.03M. As of the current estimate, Cytek BioSciences Inc’s year-ago sales were $51.5MFor the next quarter, 4 analysts are estimating revenue of $57.24M. There is a high estimate of $58.46M for the next quarter, whereas the lowest estimate is $55M.
A total of 5 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $196.65M, while the lowest revenue estimate was $195.5M, resulting in an average revenue estimate of $196.18M. In the same quarter a year ago, actual revenue was $200.45MBased on 5 analysts’ estimates, the company’s revenue will be $210.48M in the next fiscal year. The high estimate is $213.6M and the low estimate is $203.3M.
